Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis.
BALB/cAn and BALB/cJ inbred strains of mice were separated 43 yr ago, but are still very closely related because they carry the same allelomorphs at many loci. When injected 3 times i.p. with 0.5 ml of pristane (2, 6, 10, 14 tetramethylpentadecane) 11% of strain BALB/cJ develop plasmacytomas in contrast to 61% in BALB/cAn sublines. BALB/cJ first injected with pristane as neonates also developed a reduced number of plasmacytomas as compared with BALB/cAn. About 20% of pristane-treated BALB/cAn and 70% of pristane-treated BALB/cJ develop arthritis, which first appeared in the ankle joints after a latent period of 4 mo or more.
D000818:Animals; D000831:Animals, Newborn; D000843:Ankle Joint / Q000473:pathology; D001168:Arthritis / Q000139:chemically induced / Q000235:genetics*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C / Q000235:genetics*; D010954:Plasmacytoma / Q000139:chemically induced / Q000235:genetics*; D013729:Terpenes
D013729:Terpenes; C009042:pristane